Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in combination with gemcitabine, carboplatin or capecitabine in metastatic or locally advanced breast cancer after relapse on first-line chemotherapy
2010-022646-24Phase 2Completed
- Sponsor
- AB Science
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of masitinib in breast cancer (3 arms), sponsored by AB Science. Primary endpoint: Overall survival. Started Dec 2014; status: completed.
02
Drugs
masitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-022646-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022646-24.